Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · mng-umap@100

MNG628

—

c9e1cbb2-d8ae-59e2-a1f2-5723669b21c8

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
—

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • ALLOGRAFT_REJECTION+0.490
  • INTERFERON_GAMMA_RESPONSE+0.414
  • INTERFERON_ALPHA_RESPONSE+0.413
  • PROTEIN_SECRETION+0.358
  • IL6_JAK_STAT3_SIGNALING+0.338
  • INFLAMMATORY_RESPONSE+0.290
  • OXIDATIVE_PHOSPHORYLATION+0.246
  • MYC_TARGETS_V1+0.239
  • ANDROGEN_RESPONSE+0.187
  • KRAS_SIGNALING_UP+0.169

Top 10 suppressed

  • MYOGENESIS-0.386
  • EPITHELIAL_MESENCHYMAL_TRANSITION-0.373
  • APICAL_JUNCTION-0.300
  • WNT_BETA_CATENIN_SIGNALING-0.285
  • MYC_TARGETS_V2-0.272
  • ESTROGEN_RESPONSE_LATE-0.269
  • DNA_REPAIR-0.260
  • ANGIOGENESIS-0.239
  • HEDGEHOG_SIGNALING-0.219
  • HYPOXIA-0.198

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

10 twins match this tumor's tissue · 0 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1TCGA-44-2656-01A-02R-A278-07
lung-landscapes@6
—cohortMD20.862
2MNG627
mng-umap@100
——0.817
3SRR2016949
head-neck@1
——0.799
4SRR8518312
breast-umap@18
—D0.797
5SRR8518386
breast-umap@18
—D0.786
6TCGA-44-3918-01A-01R-A278-07
lung-landscapes@6
—cohortMD20.780
7aMVAC.P_006_TURBT_S224
bladder-landscape@3
——0.772
8MNG97
mng-umap@100
——0.771
99bc1133d-a577-4f31-bf6b-50748c60da80
colon-landscapes@1
——0.766
10ULC0563T_S23
lung-landscapes@6
—cohortMD20.762

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 22 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
ALLOGRAFT_REJECTION0.490Idelalisib— uncovered
INTERFERON_GAMMA_RESPONSE0.414Idelalisib— uncovered
INTERFERON_ALPHA_RESPONSE0.413Inavolisib— uncovered
PROTEIN_SECRETION0.358Remibrutinib— uncovered
IL6_JAK_STAT3_SIGNALING0.338Inavolisib— uncovered
INFLAMMATORY_RESPONSE0.290Idelalisib— uncovered
OXIDATIVE_PHOSPHORYLATION0.246Remibrutinib— uncovered
MYC_TARGETS_V10.239Inavolisib— uncovered
ANDROGEN_RESPONSE0.187Inavolisib— uncovered
KRAS_SIGNALING_UP0.169Inavolisib— uncovered
TGF_BETA_SIGNALING0.134Inavolisib— uncovered
PI3K_AKT_MTOR_SIGNALING0.112Inavolisib— uncovered
COMPLEMENT0.108Inavolisib— uncovered
MTORC1_SIGNALING0.101Inavolisib— uncovered
BILE_ACID_METABOLISM0.088Inavolisib— uncovered
FATTY_ACID_METABOLISM0.086Inavolisib— uncovered
UV_RESPONSE_DN0.082Inavolisib— uncovered
PEROXISOME0.066Idelalisib— uncovered
IL2_STAT5_SIGNALING0.057Idelalisib— uncovered
ADIPOGENESIS0.037Inavolisib— uncovered